Frank Tsai

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann et al. · Journal of Nuclear Medicine · 2019 · 262 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian et al. · Journal of Clinical Oncology · 2016 · 78 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung et al. · Investigational New Drugs · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Jason J. Luke, Fabrice Barlési, Ki Y. Chung et al. · Journal for ImmunoTherapy of Cancer · 2021 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Amita Patnaik, Michael S. Gordon, Frank Tsai et al. · Cancer Chemotherapy and Pharmacology · 2018 · 56 citations · Full text

Pharmacy, Oncology, Pharmacology +17